yeztugo hiv - Search News

News

HIV, CVS health and Gilead Sciences

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying.

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying. Executives at Gilead Sciences, the biotech behind a long list of HIV treatments and preventative medicines, have spoken with great optimism in recent weeks about the prospects that insurers will cover Yeztugo, their new HIV prevention shot .

Fierce Pharma · 1d

For now, CVS declines to cover Gilead's long-acting HIV PrEP treatment Yeztugo

· 1d · on MSN

Exclusive: CVS holds off adding Gilead’s new HIV prevention shot to drug coverage lists

STAT2d

Pharmalittle: We’re reading about Gilead’s HIV drug, FDA speeding review of a rare disease drug, and more

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...

Seeking Alpha1mon

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for ...

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025 Jul. 14, 2025 9:30 AM ET Gilead Sciences, Inc. (GILD) ...

The Herald on MSN11d

Yeztugo: Life-saving HIV prevention injection costs $28,000 a year

Gilead Sciences has secured approval from the United States health authorities for its new HIV prevention injection, Yeztugo, but concerns are growing over its steep price tag.

GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?

Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP ...

From Stagnation To Surge: Gilead Sciences Is Entering Its Next Growth Wave

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading below its intrinsic value. See more.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results